INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, focusing on potential securities fraud or unlawful business practices by the company and its officers [1][5] Company Developments - On March 18, 2025, Sarepta disclosed the death of a patient with Duchenne muscular dystrophy following treatment with its drug ELEVIDYS, resulting in a stock price drop of $27.81 per share, or 27.44%, closing at $73.54 [3] - On June 16, 2025, Sarepta reported a second fatality from acute liver failure in a patient treated with ELEVIDYS, leading to the halting of its ongoing clinical trial and a temporary suspension of the drug's distribution for non-ambulatory patients. This news caused Sarepta's stock price to fall by $15.24 per share, or 42.12%, closing at $20.94 [4]